MCID: DRY001
MIFTS: 50

Dry Eye Syndrome

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Dry Eye Syndrome

MalaCards integrated aliases for Dry Eye Syndrome:

Name: Dry Eye Syndrome 12 15 17
Dry Eye Syndromes 54 44 71
Tear Film Insufficiency 12
Dry Eye Disease 12
Xerophthalmia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10140
MeSH 44 D015352
NCIt 50 C34553
SNOMED-CT 67 193980001
ICD10 32 H04.12
UMLS 71 C0013238 C0043349

Summaries for Dry Eye Syndrome

Disease Ontology : 12 A lacrimal apparatus disease that is characterized by persistent irritation or burning of the coreneal surface.

MalaCards based summary : Dry Eye Syndrome, also known as dry eye syndromes, is related to keratoconjunctivitis sicca and keratitis, hereditary, and has symptoms including dryness of eye and dacryops. An important gene associated with Dry Eye Syndrome is AQP5 (Aquaporin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dimenhydrinate and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and thyroid, and related phenotypes are digestive/alimentary and vision/eye

Wikipedia : 74 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Dry Eye Syndrome

Diseases related to Dry Eye Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 364)
# Related Disease Score Top Affiliating Genes
1 keratoconjunctivitis sicca 31.7 TNF NGF MUC5AC LTF LACRT AQP5
2 keratitis, hereditary 31.2 TNF NGF IL6 FGF2
3 keratoconjunctivitis 31.1 TNF NGF MUC5AC IL6
4 rosacea 30.7 TNF S100A8 IL6
5 eye disease 30.7 TNF MUC5AC LACRT IL6 FGF2 EGF
6 migraine with or without aura 1 30.7 TNF NGF IL6 BDNF
7 trachoma 30.5 TNF IL6 EGF
8 fibromyalgia 30.5 TNF NGF IL6 BDNF
9 irritable bowel syndrome 30.5 TNF NGF IL6 BDNF
10 keratoconus 30.4 TNF PIP IL6 AQP5
11 eyelid disease 30.4 TNF LCN1 LACRT
12 corneal ulcer 30.4 NGF MUC5AC LACRT
13 corneal disease 30.4 TNF NGF LACRT IL6 FGF2
14 chronic fatigue syndrome 30.4 TNF IL6 BDNF
15 mental depression 30.3 TNF IL6 BDNF
16 duodenal ulcer 30.3 TNF S100A8 IL6
17 mucositis 30.2 FGF7 EGF CD44
18 chronic conjunctivitis 30.2 TNF MUC5AC IL6
19 sleep apnea 30.2 TNF IL6 BDNF
20 crohn's disease 30.2 TNF S100A8 LTF IL6
21 blepharitis 30.1 TNF PIP MUC5AC MUC4 LTF LCN1
22 peptic ulcer disease 30.0 TNF S100A8 MUC5AC
23 macular degeneration, age-related, 1 30.0 TNF IL6 FGF2 EGF BDNF
24 peripheral nervous system disease 30.0 TNF NGF IL6 FGF2 EGF CD44
25 anxiety 30.0 TNF NGF IL6 BDNF
26 skin disease 29.9 TNF IL6 FGF7 FGF2 BDNF
27 osteoporosis 29.9 TNF IL6 FGF2 EGF CD44 BDNF
28 limbal stem cell deficiency 29.8 MUC5AC MUC4 MUC1
29 inflammatory bowel disease 29.6 TNF S100A8 MUC5AC LTF IL6 FGF7
30 filamentary keratitis 29.6 MUC5AC MUC4 MUC1 LCN1 LACRT
31 cystic fibrosis 28.8 TNF S100A8 P2RY2 MUC5AC MUC4 MUC1
32 premature menopause 11.0
33 sjogren syndrome 10.5
34 external pathological resorption 10.5 TNF IL6
35 scorpion envenomation 10.5 TNF IL6
36 physiological polycythemia 10.5 TNF IL6
37 idiopathic anterior uveitis 10.5 TNF IL6
38 streptococcal toxic-shock syndrome 10.5 TNF IL6
39 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 TNF IL6
40 graft-versus-host disease 10.4
41 cardiogenic shock 10.4 TNF IL6
42 adamantinoma of long bones 10.4 FGF2 EGF
43 autoimmune gastritis 10.4 TNF IL6 EGF
44 gingival recession 10.4 TNF PRR4 IL6
45 vulvar eccrine porocarcinoma 10.4 PIP MUC1
46 pouchitis 10.4 TNF LTF
47 chronic follicular conjunctivitis 10.4 PRR4 LCN1 LACRT
48 nodular hidradenoma 10.4 PIP MUC1
49 rheumatoid arthritis interstitial lung disease 10.4 TNF MUC1
50 autoimmune disease of exocrine system 10.4 TNF IL6 AQP5

Graphical network of the top 20 diseases related to Dry Eye Syndrome:



Diseases related to Dry Eye Syndrome

Symptoms & Phenotypes for Dry Eye Syndrome

UMLS symptoms related to Dry Eye Syndrome:


dryness of eye, dacryops

MGI Mouse Phenotypes related to Dry Eye Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 AQP5 BDNF CD44 EGF IL6 MUC5AC
2 vision/eye MP:0005391 9.32 AQP5 BDNF CD44 EGF FGF2 FGF7

Drugs & Therapeutics for Dry Eye Syndrome

Drugs for Dry Eye Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimenhydrinate Approved Phase 4 523-87-5 441281
2
Ethanol Approved Phase 4 64-17-5 702
3
Sorbitol Approved Phase 4 50-70-4 5780
4
Bromfenac Approved Phase 4 91714-94-2 60726
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Ofloxacin Approved Phase 4 82419-36-1 4583
7
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
8
Rebamipide Approved, Investigational Phase 4 90098-04-7
9
Glycerol Approved, Investigational Phase 4 56-81-5 753
10
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
11
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
12
Povidone Approved Phase 4 9003-39-8 131751496
13
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
14
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
15
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
16
Travoprost Approved Phase 4 157283-68-6 5282226
17
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
18
Menthol Approved Phase 4 2216-51-5 16666
19
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
20
Azithromycin Approved Phase 4 83905-01-5 55185 447043
21
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
28
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
29
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
30
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
31
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
32
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
33
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35 Carboxymethylcellulose Sodium Phase 4
36 Dextrans Phase 4
37 Plasma Substitutes Phase 4
38 Anticoagulants Phase 4
39 Blood Substitutes Phase 4
40 Cathartics Phase 4
41 Laxatives Phase 4
42 Olive Phase 4
43 Castor Phase 4
44 Analgesics, Non-Narcotic Phase 4
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4
46 Analgesics Phase 4
47 Anti-Bacterial Agents Phase 4
48 Guar Phase 4
49 Cytochrome P-450 Enzyme Inhibitors Phase 4
50 Anti-Ulcer Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 719)
# Name Status NCT ID Phase Drugs
1 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
2 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
3 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
4 Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy Unknown status NCT03747614 Phase 4 Fluorometholone
5 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
6 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
7 A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis Unknown status NCT03237936 Phase 4 1mg/mL ciclosporin
8 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
9 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
10 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
11 The Effect of Ocular Surface Lubricant Eyedrops on Lid Parallel Conjunctival Folds (LIPCOF) and Other Signs and Symptoms of Dysfunctional Tear Syndrome Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
12 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
13 A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
14 Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
15 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
16 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4 Lubricant Eye Drops (Optive™);Lubricating Eye Drops (blink® Tears)
17 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
18 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
19 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
20 Refractive Surgery and Optive Compatibility Study Completed NCT00469157 Phase 4 Optive
21 Soothe Versus Refresh Completed NCT00284999 Phase 4 Soothe;Refresh Tears
22 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
23 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
24 Evaluation of Maintaining Visual Performance Of Subjects Who Engage in Electronic Visual Tasking While Using Restasis (EMPOWER) Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
25 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
26 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
27 Tear Lipid Layer Thickness With Emollient Eye Drops Completed NCT03380624 Phase 4 Refresh Optive;Refresh Optive MEGA-3
28 Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02986750 Phase 4
29 Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye Completed NCT04184999 Phase 4 dexamethasone intraocular suspension, 9%;Prednisolone Acetate 1% Oph Susp
30 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
31 A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
32 Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study Completed NCT03608761 Phase 4 Rebamipide
33 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
34 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
35 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
36 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
37 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
38 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
39 Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Systane ® Ultra Preservative Free on Tear Film Dysfunction Syndrome From Mild to Moderate Completed NCT03223909 Phase 4 PRO-087;Systane Ultra;Systane Ultra Preservative Free
40 The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
41 Study to Evaluate the Physical Effect of SYSTANE QID in People That Have Moderate to Severe Dry Feeling Eyes Completed NCT00818909 Phase 4
42 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
43 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
44 A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine Completed NCT00407043 Phase 4 Lotemax;Restasis
45 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
46 The Utility of in Vivo Confocal Microscopy (IVCM) to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease (DED) Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
47 Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Completed NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
48 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
49 An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® Completed NCT00799682 Phase 4 Xalatan;Travatan Z
50 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast

Search NIH Clinical Center for Dry Eye Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cod Liver Oil
hydroxyethyl cellulose
retinol acetate
retinyl palmitate
Sodium Chloride
SODIUM CHLORIDE 0.9% PROCESSING SOLN
SODIUM CHLORIDE GRANULES
Vitamin A
VITAMIN A (AS ACETATE & BETA CAROTENE)
VITAMIN A (AS PALMITATE & BETA CAROTENE)
VITAMIN A (NATURAL)
VITAMIN A PALMITATE (SOLUBILIZED)

Cochrane evidence based reviews: dry eye syndromes

Genetic Tests for Dry Eye Syndrome

Anatomical Context for Dry Eye Syndrome

MalaCards organs/tissues related to Dry Eye Syndrome:

40
Eye, Liver, Thyroid, Salivary Gland, Tongue, Bone Marrow, Skin

Publications for Dry Eye Syndrome

Articles related to Dry Eye Syndrome:

(show top 50) (show all 1411)
# Title Authors PMID Year
1
A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. 61 54
18436819 2008
2
Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3. 61 54
17675493 2007
3
[Lacrimal gland-associated mucins. Age related production and their role in the pathophysiology of dry eye]. 54 61
15678360 2005
4
P2-pyrimidinergic receptors and their ligands. 54 61
12369950 2002
5
Influence of topical anesthesia on tests diagnostic of blepharitis-associated dry eye syndrome. 54 61
9145691 1997
6
Ocular surface damage and tear lactoferrin in dry eye syndrome. 54 61
7825407 1994
7
Acupuncture for dry eye syndrome after refractive surgery: A randomized controlled pilot trial. 61
32904133 2021
8
New Freeware for Image Analysis of Lissamine Green Conjunctival Staining. 61
33347000 2021
9
[Efficacy of intense pulsed light therapy in the treatment of Meibomian gland dysfunction-related severe dry eye]. 61
33358077 2021
10
Comparison of the efficacy of eyelid warming masks and artificial tears for dry eye symptoms in contact lens wearers. 61
32169321 2021
11
Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases. 61
33572327 2021
12
Non-Oncologic Applications of Nanomedicine-Based Phototherapy. 61
33504015 2021
13
Risk Factors Influencing the Occurrence and Severity of Symptomatic Dry Eye Syndrome: A Cross-sectional Study. 61
33522358 2021
14
Role of CD4+ T Helper Cells in the Development of BAC-Induced Dry Eye Syndrome in Mice. 61
33492357 2021
15
The expression of miRNA-146a-5p and its mechanism of treating dry eye syndrome. 61
32935891 2021
16
Fibromyalgia syndrome and the eye-A review. 61
32512032 2021
17
In Vivo Effect of RSH-12, a Novel Selective MMP-9 Inhibitor Peptide, in the Treatment of Experimentally Induced Dry Eye Model. 61
32567381 2021
18
Modelling of late side-effects following cranial proton beam therapy. 61
33482232 2021
19
Ocular Surface Changes in Hashimoto's Thyroiditis Without Thyroid Ophthalmopathy. 61
32097187 2021
20
Lacrimal gland atrophy and dry eye related to isotretinoin, androgen, and prolactin: differential diagnosis for Sjögren's syndrome. 61
33470346 2021
21
Multi-Disease Deep-Learning Neural Network for the Diagnosis of Corneal Diseases. 61
33529589 2021
22
Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: Report of three cases. 61
33162180 2021
23
Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma. 61
32574763 2021
24
Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. 61
32358156 2021
25
[Ocular manifestations of Crohn's disease]. 61
32950292 2020
26
Safety and Efficacy of an Augmented Intense Pulse Light Protocol for Dry Eye Syndrome and Blepharitis. 61
33370543 2020
27
Ocular Findings in Pontine Tegmental Cap Dysplasia. 61
32398424 2020
28
Generation of three induced pluripotent stem cell lines from type 2 diabetic patients with ocular complications. 61
33370876 2020
29
Molecular pharmacology of P2Y receptor subtypes. 61
33309519 2020
30
New application for assessment of dry eye syndrome induced by particulate matter exposure. 61
32949841 2020
31
Evaluation of Four Artificial Intelligence-Assisted Self-Diagnosis Apps on Three Diagnoses: Two-Year Follow-Up Study. 61
33275113 2020
32
Vitamin D deficiency is associated with dry eye syndrome: a systematic review and meta-analysis. 61
32421222 2020
33
Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome. 61
33292325 2020
34
A decrease in the tear secretion volume in a mouse model with ulcerative colitis. 61
32942916 2020
35
Tear Film Classification in Interferometry Eye Images Using Phylogenetic Diversity Indexes and Ripley's K Function. 61
32976110 2020
36
Genetically Encoded Calcium Indicators for In Situ Functional Studies of Corneal Nerves. 61
33151279 2020
37
Easy and effective test to evaluate tear-film stability for self-diagnosis of dry eye syndrome: blinking tolerance time (BTT). 61
33148200 2020
38
Changes in tear film osmolarity after 25G+ PPV. 61
33208133 2020
39
Eye pain in the white and quiet eye. 61
33009080 2020
40
Effect of Scleral Lens Wear on Central Corneal Thickness and Intraocular Pressure in Patients With Ocular Surface Disease. 61
31652178 2020
41
Ocular findings in metabolic syndrome: a review. 61
33299953 2020
42
Can Gut Microbiota Affect Dry Eye Syndrome? 61
33182758 2020
43
Clinical Manifestation and Risk Factors Associated With Remission in Patients With Filamentary Keratitis. 61
32574776 2020
44
Massive Demodicosis of the Eyes in a Patient with Sjögren Syndrome: A Case Report. 61
33128728 2020
45
Ophthalmic manifestations and management of common and rare autoimmune syndromes. 61
32769709 2020
46
Ocular cicatricial pemphigoid (Review). 61
32905166 2020
47
Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. 61
33085593 2020
48
Lactoferrin Concentration in Human Tears and Ocular Diseases: A Meta-Analysis. 61
33035290 2020
49
Association of ocular diseases with schizophrenia, bipolar disorder, and major depressive disorder: a retrospective case-control, population-based study. 61
33008365 2020
50
Therapeutic effects of acupuncture in typical dry eye: a systematic review and meta-analysis. 61
33124107 2020

Variations for Dry Eye Syndrome

Expression for Dry Eye Syndrome

Search GEO for disease gene expression data for Dry Eye Syndrome.

Pathways for Dry Eye Syndrome

Pathways related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TNF S100A8 ORM1 MUC5AC MUC4 MUC1
2
Show member pathways
13.75 TNF PIP NGF MUC1 IL6 FGF7
3
Show member pathways
13.31 TNF PIP NGF IL6 FGF7 FGF2
4
Show member pathways
13.28 TNF MUC1 IL6 FGF7 FGF2 EGF
5
Show member pathways
13.16 TNF PIP NGF IL6 FGF7 FGF2
6
Show member pathways
13.11 TNF NGF IL6 FGF7 FGF2 EGF
7
Show member pathways
12.98 NGF IL6 FGF7 FGF2 EGF BDNF
8
Show member pathways
12.96 NGF IL6 FGF7 FGF2 EGF BDNF
9
Show member pathways
12.78 TNF NGF IL6 FGF7 FGF2 EGF
10
Show member pathways
12.65 NGF FGF7 FGF2 EGF BDNF
11 12.62 TNF NGF FGF7 FGF2 EGF BDNF
12
Show member pathways
12.42 TNF NGF IL6 FGF7 FGF2 EGF
13 12.31 NGF FGF7 FGF2 EGF
14
Show member pathways
12.28 NGF IL6 FGF7 FGF2 EGF BDNF
15
Show member pathways
12.25 TNF S100A8 MUC5AC IL6
16 12.09 TNF NGF IL6 BDNF
17
Show member pathways
12.05 TNF NGF IL6 FGF7 FGF2 BDNF
18 11.96 IL6 FGF7 FGF2 EGF
19 11.88 TNF MUC1 IL6 FGF2
20
Show member pathways
11.73 TNF NGF BDNF
21 11.71 IL6 FGF2 EGF CD44
22 11.49 NGF IL6 FGF7 FGF2 EGF BDNF
23 11.48 TNF IL6 FGF7
24 11.44 IL6 FGF2 EGF
25 11.38 FGF7 FGF2 EGF
26 11.25 NGF FGF2 EGF CD44 BDNF
27 10.82 TNF IL6 FGF7 FGF2 EGF
28 10.66 TNF PIP NGF IL6 FGF7 FGF2

GO Terms for Dry Eye Syndrome

Cellular components related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 S100A8 PIP ORM1 MUC5AC MUC4 MUC1
2 extracellular region GO:0005576 9.89 TNF S100A8 PRR4 PIP ORM1 NGF
3 extracellular space GO:0005615 9.55 TNF S100A8 PRR4 PIP ORM1 NGF
4 Golgi lumen GO:0005796 9.46 NGF MUC5AC MUC4 MUC1

Biological processes related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.91 TNF S100A8 LTF LACRT
2 inflammatory response GO:0006954 9.85 TNF S100A8 ORM1 IL6 CD44
3 positive regulation of gene expression GO:0010628 9.8 TNF PIP NGF IL6 FGF7 FGF2
4 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.73 TNF NGF CD44
5 positive regulation of protein kinase B signaling GO:0051897 9.73 TNF FGF7 FGF2 EGF
6 positive regulation of epithelial cell proliferation GO:0050679 9.71 LACRT FGF7 FGF2
7 positive regulation of MAP kinase activity GO:0043406 9.69 TNF FGF2 EGF
8 O-glycan processing GO:0016266 9.67 MUC5AC MUC4 MUC1
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.67 TNF S100A8 LTF IL6
10 humoral immune response GO:0006959 9.65 TNF LTF IL6
11 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL6
12 nerve growth factor signaling pathway GO:0038180 9.6 NGF BDNF
13 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 9.59 LTF LACRT
14 regulation of protein localization to cell surface GO:2000008 9.58 EGF BDNF
15 negative regulation of lipid storage GO:0010888 9.58 TNF IL6
16 positive regulation of interleukin-1 beta production GO:0032731 9.58 TNF ORM1 IL6
17 regulation of immune system process GO:0002682 9.57 PIP ORM1
18 positive regulation of collateral sprouting GO:0048672 9.55 NGF BDNF
19 vascular endothelial growth factor production GO:0010573 9.52 TNF IL6
20 retina homeostasis GO:0001895 9.46 PRR4 PIP LTF LCN1
21 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.35 LACRT IL6 FGF7 EGF CD44
22 positive regulation of epithelial tube formation GO:1905278 9.32 FGF2 EGF
23 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.02 TNF NGF IL6 CD44 BDNF

Molecular functions related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 TNF S100A8 PRR4 PIP P2RY2 ORM1
2 growth factor activity GO:0008083 9.17 NGF LACRT IL6 FGF7 FGF2 EGF
3 nerve growth factor receptor binding GO:0005163 8.96 NGF BDNF

Sources for Dry Eye Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....